Olink (now part of Thermo Fisher Scientific) is a proteomics company with technology that measures thousands of protein biomarkers at the same time. Their public platform had become so fragile that it crashed and no one wanted to change it. We rebuilt it into something stable, secure and theirs to run.
Founded in Uppsala, Olink builds high-throughput proteomics: their Proximity Extension Assay (PEA) technology measures thousands of protein biomarkers from a single sample, and their catalogue is referenced in over 4,000 peer-reviewed publications across cancer, cardiovascular, neurological and inflammatory disease.
It is deeply scientific, deeply detailed work, every biomarker carries its own description, disease-risk associations and normal ranges.
The problem was not the science. It was the website.
Their public platform had grown into something fragile and tangled. It crashed, and no one on the team dared touch it for fear of breaking it further. For a company this far along, that was untenable: the site is where the entire product catalogue, the document library and Olink Insight all meet the world.
We rebuilt the platform from the ground up as a decoupled architecture: a fast, resilient front end in Next.js and React on a headless WordPress CMS. At its core is a modular page builder with a kit of reusable content modules the Olink team assembles themselves. Olink's editors publish product pages, documents, FAQs, webinars and publication listings themselves, without the old fragility.
It is an integration platform as much as a website:
“We showed the new site to Olink's C-suite. Everyone was seriously impressed: that we pulled it off at all, how good it looked, and how good the site felt.”
The Olink team now owns their platform again.
They run the product catalogue and publish across documents, FAQs, webinars and publication listings themselves, curating a document library of 260+ white papers, guides and reports. Each tagged by product and downloadable. All without fear of the site going down.
Deep-linked from it, Olink Insight keeps every biomarker’s disease-risk associations and normal ranges, drawn from more than 50,000 individuals across three cohorts and three continents.
What was a liability nobody wanted to touch is now an asset the whole company builds on: a dependable, editable foundation for one of proteomics’ most detailed bodies of knowledge.
Olink had a site no one dared to change. We gave them a platform they run with confidence.
Fast, secure, and fully in their hands. When the science is this detailed, the platform carrying it has to be dependable.
Want to know more about this project or how we work, contact Simon.
We rebuilt Olink’s into something stable, secure and theirs to run. Tell us about yours.
